Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities: 2021-2025

Historic Total Current Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $123.6 million.

  • Kiniksa Pharmaceuticals International's Total Current Liabilities rose 28.80% to $123.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.6 million, marking a year-over-year increase of 28.80%. This contributed to the annual value of $100.6 million for FY2024, which is 58.05% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Total Current Liabilities of $123.6 million as of Q3 2025, which was up 4.89% from $117.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Total Current Liabilities registered a high of $123.6 million during Q3 2025, and its lowest value of $34.4 million during Q3 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Total Current Liabilities value was $84.3 million (recorded in 2024), while the average stood at $80.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first dropped by 27.34% in 2023, then skyrocketed by 79.46% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Total Current Liabilities (Quarterly) stood at $44.8 million in 2021, then rose by 5.00% to $47.1 million in 2022, then skyrocketed by 35.27% to $63.7 million in 2023, then skyrocketed by 58.05% to $100.6 million in 2024, then grew by 28.80% to $123.6 million in 2025.
  • Its Total Current Liabilities stands at $123.6 million for Q3 2025, versus $117.8 million for Q2 2025 and $97.3 million for Q1 2025.